GTF2E2

GTF2E2 encodes TFIIEβ, the beta subunit of the general transcription factor TFIIE, which directly interacts with TFIIH to enable RNA polymerase II transcription initiation (PMID:26996949). TFIIEβ functions as a rate-limiting subunit for TFIIE complex assembly: its depletion lowers the abundance of its heterodimeric partner GTF2E1 (TFIIEα), reflecting stoichiometric buffering of complex levels (PMID:29032074), and destabilizing homozygous missense mutations reduce levels of both subunits, decrease TFIIEα phosphorylation, and produce a temperature-sensitive transcription defect (PMID:26996949, PMID:28973399). These mutations cause tissue-specific differentiation failures—most notably a late-stage erythroid/hematopoietic defect with hemoglobin subunit imbalance—while leaving nucleotide excision repair of UV damage intact, establishing that the phenotype is a transcription deficiency rather than a DNA repair defect (PMID:26996949, PMID:28973399). In cancer contexts, GTF2E2 has been reported to physically associate with RPS4X and to act through mTOR signaling in lung adenocarcinoma (PMID:33757492), and to transcriptionally regulate target genes including FUS via AKT/ERK/mTOR signaling in esophageal carcinoma (PMID:34853466). Beyond these findings, structural and biochemical details of how TFIIEβ engages the preinitiation complex are not further characterized in the available corpus.

1. 2016 High

   Established GTF2E2 as TFIIEβ and showed that its missense mutations destabilize the whole TFIIE complex while sparing DNA repair, separating transcription from NER function.

   Evidence Patient cell lines with homozygous missense mutations, western blotting, phosphorylation and UV-repair assays

   PMID:26996949

   Open questions at the time

   • Does not resolve the structural basis of TFIIE–TFIIH interaction
   • Mechanism linking complex destabilization to specific gene programs not defined
2. 2017 High

   Demonstrated that mutant TFIIEβ causes a temperature-sensitive transcription defect with a tissue-specific (erythroid) differentiation failure, confirming a transcription-based, repair-independent pathology.

   Evidence Patient-derived iPS cells, in vitro erythroid differentiation, temperature-sensitivity and protein quantification

   PMID:28973399

   Open questions at the time

   • Why erythropoiesis is selectively sensitive remains unexplained
   • Target genes driving the differentiation block not identified
3. 2017 Medium

   Showed that GTF2E2 is rate-limiting for TFIIE assembly, with its level controlling GTF2E1 abundance through stoichiometric post-transcriptional buffering.

   Evidence Integration of CPTAC/TCGA proteomics-genomics with experimental confirmation of the GTF2E2–GTF2E1 interaction

   PMID:29032074

   Open questions at the time

   • Specific experimental method for confirmation not detailed in abstract
   • Degradation mechanism of unassembled GTF2E1 not defined
4. 2021 Medium

   Implicated GTF2E2 in cancer by identifying a physical RPS4X interaction and an mTOR-mediated pro-tumorigenic role in lung adenocarcinoma.

   Evidence shRNA knockdown, LC-MS/MS proteomics, proliferation/migration/invasion assays, xenografts, mTOR pathway analysis

   PMID:33757492

   Open questions at the time

   • No biochemical reconstitution of the GTF2E2–RPS4X interaction
   • How a general transcription factor links to mTOR signaling is not mechanistically dissected
5. 2021 Medium

   Showed GTF2E2 transcriptionally activates FUS and drives ESCC progression via AKT/ERK/mTOR, with miR-139-5p/Ago2 repressing GTF2E2.

   Evidence Promoter interaction and Ago2-binding assays, rescue experiments, in vitro and xenograft models, pathway analysis

   PMID:34853466

   Open questions at the time

   • Direct promoter occupancy vs. indirect effect not fully separated
   • Single-lab finding without independent replication
6. 2023 Low

   Extended the cancer role by linking GTF2E2 to CCND1 transcriptional regulation and miR-340-5p control in glioblastoma.

   Evidence Proliferation, colony formation, TUNEL, migration assays, xenograft, miR-340-5p target validation

   PMID:37845349

   Open questions at the time

   • Direct vs. indirect CCND1 regulation unresolved ('directly or indirectly')
   • Single-lab, mechanistically thin
   • No biochemical demonstration of GTF2E2 binding the CCND1 promoter

• How TFIIEβ engages the RNA Pol II preinitiation complex and TFIIH at structural resolution, and how a core general transcription factor selectively shapes tissue-specific and oncogenic gene programs, remain open.
• No structural model of TFIIE in the PIC in the corpus
• Mechanism of selective target gene control unexplained
• Cancer-context interactions not reconciled with general transcription role